IntelGenx Technologies Corp. IGX IGXT, a drug delivery company focused on the development and manufacturing of pharmaceutical films, reported its financial results on Monday for the second quarter ending on June 30, 2023.
IntelGenx: 67% Revenue Dip, Strategic Successes - Can It Turn The Tide?
During this period, IntelGenx reported total revenues of $133,000, marking a 67% decrease compared to the previous year's figure of $398,000.
The decrease primarily resulted from reductions in R&D revenues by $260,000 and royalties on product sales by $5,000.
"We've achieved a significant milestone this quarter, completing enrollment in our BUENA study," stated Dwight Gorham who was recently appointed CEO. "A Health Canada-approved design change will enhance study efficiency, allowing us to detect Montelukast VersaFilm effects with fewer patients.”
"We've also met our short-term commercial goals, signing a binding term sheet with a CDMO customer for oral film packaging services. This pact is set to yield around $9 million over three years, bolstering our revenue stream and advancing our growth strategy."
Operating Costs Increase Marginally
Operating costs and expenses for Q2 2023 totaled $2.7 million, slightly higher than the corresponding period of 2022 at $2.6 million.
The company reported this change is mainly due to increased R&D expenses by $27,000 and selling, general, and administrative expenses by $101,000. However, these were partially offset by decreases in manufacturing expenses by $45,000 and tangible asset depreciation by $1,000.
Consequently, IntelGenx reported an operating loss of $2.5 million for Q2 2023, compared to an operating loss of $2.2 million for the same period in 2022.
Net Comprehensive Loss, Cash and Investments
- The net comprehensive loss for the quarter ended June 30, 2023, amounted to $3.0 million, or $0.02 per basic and diluted share. This reflects a modest improvement from the net comprehensive loss of $3.2 million, or $0.02 per basic and diluted share, reported in the corresponding period of 2022.
- As of June 30, 2023, IntelGenx held cash and short-term investments totaling $1.3 million, highlighting the company's ongoing commitment to navigating the evolving pharmaceutical landscape while addressing financial considerations.
Price Action
IGXT's stocks were trading lower by 13.51% at $0.16 per share at the time of market close.
The Benzinga Cannabis Capital Conference, the place where deals get done, is returning to Chicago this Sept 27-28 for its 17th edition. Get your tickets today before prices increase and secure a spot at the epicenter of cannabis investment and branding.
Photo: Steve Buissinne via Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Click on the image for more info.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry?
Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.
Get your tickets now before prices surge by following this link.